Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 vs placebo and dulaglutide in type 2 diabetes mellitus
CTR20211733Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2021
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in type 2 diabetes mellitus (T2DM), sponsored by Innovent Biologics. Started Jul 2021; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20211733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211733.